Q4 EPS Estimate for Guardant Health Increased by Analyst

Guardant Health, Inc. (NASDAQ:GH - Free Report) - Investment analysts at Leerink Partnrs lifted their Q4 2024 earnings estimates for shares of Guardant Health in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.73) per share for the quarter, up from their previous estimate of ($0.76). The consensus estimate for Guardant Health's current full-year earnings is ($3.44) per share. Leerink Partnrs also issued estimates for Guardant Health's Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.54) EPS and FY2026 earnings at ($2.86) EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business had revenue of $191.48 million for the quarter, compared to analysts' expectations of $170.49 million. During the same quarter last year, the firm earned ($0.73) earnings per share. The firm's quarterly revenue was up 33.9% compared to the same quarter last year.

GH has been the topic of several other reports. Barclays initiated coverage on Guardant Health in a research report on Thursday. They set an "overweight" rating and a $60.00 price target on the stock. Sanford C. Bernstein dropped their target price on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price target on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Leerink Partners dropped their price objective on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. Finally, The Goldman Sachs Group increased their price target on shares of Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Sixteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health currently has an average rating of "Buy" and a consensus price target of $41.81.

Guardant Health Trading Up 2.9 %

Shares of NASDAQ:GH traded up $1.36 on Thursday, hitting $48.56. 1,943,584 shares of the company were exchanged, compared to its average volume of 2,715,411. The firm has a market capitalization of $6.00 billion, a P/E ratio of -11.47 and a beta of 1.28. Guardant Health has a 1-year low of $15.81 and a 1-year high of $49.86. The stock's 50 day moving average price is $34.53 and its 200 day moving average price is $29.26.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company's stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the company's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now owns 7,648 shares of the company's stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,548 shares of company stock worth $179,782 in the last quarter. 5.50% of the stock is owned by insiders.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock worth $232,325,000 after buying an additional 6,618,785 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after acquiring an additional 1,137,482 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company's stock valued at $34,701,000 after purchasing an additional 1,059,104 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Guardant Health in the third quarter valued at approximately $21,389,000. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Guardant Health during the 3rd quarter worth approximately $15,624,000. Institutional investors and hedge funds own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.